Transcriptional regulation of telomerase activity: Roles of the the ets transcription factor family

Annals of the New York Academy of Sciences

Volumn 1114, Issue , 2007, Pages 36-47

  Dwyer, Julie ^a   Li, H E ^a   Xu, Dakang ^a   Lui, Jun Ping ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

Author keywords

Cancer; Ets; hTERT; Senescence; Telomerase; Telomeres; Transcription factor; Tumorigenesis

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR ER81;

CELL DIFFERENTIATION; CONFERENCE PAPER; FIBROBLAST; GENE EXPRESSION; GENE MUTATION; GENETIC REGULATION; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; ONCOGENE C MYC; PROTO ONCOGENE; STEM CELL;

EID: 35948992285     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1396.022     Document Type: Conference Paper

References (65)

1. HERBIG, U. et al. 2006. Cellular senescence in aging primates. Science 311: 1257.
2. BLACKBURN, E.H. 2001. Switching and signaling at the telomere. Cell 106: 661-673.
3. BLACKBURN, E.H. 2005. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett. 579: 859-862.
4. DE LANGE, T. 2004. T-loops and the origin of telomeres. Nat. Rev. Mol. Cell Biol. 5: 323-329.
5. SHAY, J.W. & W.E. WRIGHT. 2007. Hallmarks of telomeres in ageing research. J. Pathol. 211: 114-123.
6. EPEL, E.S. et al. 2004. Accelerated telomere shortening in response to life stress. Proc. Natl. Acad. Sci. USA 101: 17312-17315.
7. BODNAR, A.G. et al. 1998. Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349-352.
8. YANG, G. et al. 2007. Disruption of the retinoblastoma pathway by small interfering RNA and ectopic expression of the catalytic subunit of telomerase lead to immortalization of human ovarian surface epithelial cells. Oncogene 26: 1492-1498.
9. LIU, J.P. 1999. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J. 13: 2091-2104.
10. BAYNE, S. & J.P. LIU. 2005. Hormones and growth factors regulate telomerase activity in ageing and cancer. Mol. Cell Endocrinol. 240: 11-22.
11. LIU, J.P. et al. 2006. Mechanisms of cell immortalization mediated by EB viral activation of telomerase in nasopharyngeal carcinoma. Cell Res. 16: 809-817.
12. SHAY, J.W. & W.E. WRIGHT. 2005. Mechanism-based combination telomerase inhibition therapy. Cancer Cell 7: 1-2.
13. KELLAND, L.R. 2005. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics: current status and future prospects. Eur. J. Cancer 41: 971-979.
14. LI, S. et al. 2005. Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. J. Biol. Chem. 280: 23709-23717.
15. DIKMEN, Z.G. et al. 2005. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res. 65: 7866-7873.
16. GELLERT, G.C. et al. 2006. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res. Treat. 96: 73-81.
17. LIU, J.P. 2001. Molecular mechanisms regulating telomerase activity. In Telomerase, Aging and Disease. M.P. Mattson & T. Pandita, Eds.: 33-59. Elsevier Science. Amsterdam, the Netherlands.
18. LIU, J.P. et al. 2002. Regulation of telomerase activity. In Telomeres and Telomerases: Cancer and Biology. G. Krupp & R. Parwaresch, Eds.: 134-159. Landes Bioscience/Eurekah. Austin, TX.
19. NAKAMURA, T.M. et al. 1997. Telomerase catalytic subunit homologs from fission yeast and human. Science 277: 955-959.
20. MEYERSON, M. et al. 1997. hEst2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90: 785-795.
21. NAKAYAMA, J. et al. 1997. TLP1: a gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family. Cell 88: 875-884.
22. HARRINGTON, L. et al. 1997. A mammalian telomerase-associated protein. Science 275: 973-977.
23. KILIAN, A. et al. 1997. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet. 6: 2011-2019.
24. COLLINS, K. & J.R. MITCHELL. 2002. Telomerase in the human organism. Oncogene 21: 564-579.
25. KELLEHER, C. et al. 2002. Telomerase: biochemical considerations for enzyme and substrate. Trends Biochem. Sci. 27: 572-579.
26. HOLT, S.E. et al. 1999. Functional requirement of p23 and hsp90 in telomerase complexes. Genes Dev. 13: 817-826.
27. KEPPLER, B.R. et al. 2006. The biochemical role of the heat shock protein 90 chaperone complex in establishing human telomerase activity. J. Biol. Chem. 281: 19840-19848.
28. LI, H. et al. 1998. Telomerase is controlled by protein kinase Calpha in human breast cancer cells. J. Biol. Chem. 273: 33436-33442.
29. LI, H. et al. 1997. Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells. J. Biol. Chem. 272: 16729-16732.
30. CONG, Y.S. et al. 1999. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter [In Process Citation]. Hum. Mol. Genet. 8: 137-142.
31. HORIKAWA, I. et al. 1999. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene [In Process Citation]. Cancer Res. 59: 826-830.
32. TAKAKURA, M. et al. 1999. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 59: 551-557.
33. LI, H. et al. 2005. Telomerase down-regulation does not mediate PC12 pheochromocytoma cell differentiation induced by NGF, but requires MAP kinase signalling. J. Neurochem. 95: 891-901.
34. LI, H. et al. 2006. Transforming growth factor beta suppresses human telomerase reverse transcriptase (hTERT) by smad3 interactions with c-myc and the hTERT gene. J. Biol. Chem. 281: 25588-25600.
35. XU, D. et al. 2001. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc. Natl. Acad. Sci. USA 98: 3826-3831.
36. SARKAR, P. et al. 2006. Activation of telomerase in BeWo cells by estrogen and 2,3,7,8-tetrachlorodibenzo-p-dioxin in co-operation with c-Myc. Int. J. Oncol. 28: 43-51.
37. XU, D. et al. 2006. Inhibition of telomerase targeting MAP kinase signaling. In Methods in Molecular Biology: telomerase Inhibition: strategies and Protocols: L. G. Andrews & T. O. Tollefsbol, Eds.: in press. Humana Press Inc. Totowa, NJ.
38. TAKAKURA, M. et al. 2005. Function of AP-1 in transcription of the telomerase reverse transcriptase gene (TERT) in human and mouse cells. Mol. Cell. Biol. 25: 8037-8043.
39. MAIDA, Y. et al. 2002. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene 21: 4071-4079.
40. GOUELI, B.S. & R. JANKNECHT. 2004. Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu, Ras, or Raf. Mol. Cell Biol. 24: 25-35.
41. WANG, Z. et al. 2000. Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway [In Process Citation]. Cancer Res. 60: 5376-5381.
42. ALFONSO-DE MATTE, M.Y. et al. 2002. Telomerase is regulated by c-Jun NH2-terminal kinase in ovarian surface epithelial cells. Cancer Res. 62: 4575-4578.
43. SHARROCKS, A.D. 2001. The ETS-domain transcription factor family. Nat. Rev. Mol. Cell Biol. 2: 827-837.
44. SEMENTCHENKO, V.I. & D.K. WATSON. 2000. Ets target genes: past, present and future. Oncogene 19: 6533-6548.
45. MAROULAKOU, I.G. & D.B. BOWE. 2000. Expression and function of Ets transcription factors in mammalian development: a regulatory network. Oncogene 19: 6432-6442.
46. HSU, T. et al. 2004. Ets proteins in biological control and cancer. J. Cell Biochem. 91: 896-903.
47. SVENSSON, S. et al. 2005. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 24: 4370-4379.
48. BUGGY, Y. et al. 2006. Ets2 transcription factor in normal and neoplastic human breast tissue. Eur. J. Cancer 42: 485-491.
49. SHARROCKS, A.D. 2001. The ETS-domain transcription factor family. Nat. Rev. Mol. Cell Biol. 2: 827-837.
50. MYERS, E. et al. 2005. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clin. Cancer Res. 11: 2111-2122.
51. SETH, A. & D.K. WATSON. 2005. ETS transcription factors and their emerging roles in human cancer. Eur. J. Cancer 41: 2462-2478.
52. SAPI, E. et al. 1998. Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 breast carcinoma cells. Cancer Res. 58: 1027-1033.
53. FOOS, G. & C.A. HAUSER. 2000. Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness. Oncogene 19: 5507-5516.
54. CARBONE, G.M. et al. 2004. Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. Nucleic Acids Res. 32: 4358-4367.
55. HAHNE, J.C. et al. 2005. Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth. Oncogene 24: 5384-5388.
56. NEZNANOV, N. et al. 1999. A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice. Cancer Res. 59: 4242-4246.
57. SEMENTCHENKO, V.I. et al. 1998. ETS2 function is required to maintain the transformed state of human prostate cancer cells. Oncogene 17: 2883-2888.
58. OIKAWA, T. & T. YAMADA. 2003. Molecular biology of the Ets family of transcription factors. Gene 303: 11-34.
59. XU, D. et al. 2002. Ets1 is required for p53 transcriptional activity in UV-induced apoptosis in embryonic stem cells. EMBO J. 21: 4081-4093.
60. XIAO, X. et al. 2002. Identification and characterization of rapidly dividing U937 clones with differential telomerase activity and gene expression profiles: role of c-Myc/Mad1 and Id/Ets proteins. Leukemia 16: 1877-1880.
61. XIAO, X. et al. 2003. Role of Ets/Id proteins for telomerase regulation in human cancer cells. Exp. Mol. Pathol. 75: 238-247.
62. ROUSSEL, M.F. et al. 1994. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1. Oncogene 9: 405-415.
63. TAKAHASHI, A. et al. 2003. EWS/ETS fusions activate telomerase in Ewing's tumors. Cancer Res. 63: 8338-8344.
64. SHINDOH, M. et al. 2004. E1AF, an ets-oncogene family transcription factor. Cancer Lett. 216: 1-8.
65. HSU, C.P. et al. 2006. Ets2 binding site single nucleotide polymorphism at the hTERTgene promoter-effect on telomerase expression and telomere length maintenance in non-small cell lung cancer. Eur. J. Cancer 42: 1466-1474.